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Recently developed antibodies against uroplakin II and
DNp63 (p40) show utility in diagnosing primary bladder
urothelial carcinoma, although application in metastatic
bladder cancer and patient outcomes has been less well
defined. We evaluated these antibodies by immunostain
intensity and H-score, in conjunction with GATA-3 immu-
noreactivity, in 89 patients with muscle-invasive urothelial
carcinoma and 35 paired metastasis. The maintenance of
immunoreactivity in metastatic lesions and the association
to disease recurrence and survival was assessed. Bladder
urothelial carcinoma showed immunoreactivity for GATA-3
in 99% (88/89), p40 in 87% (77/89) and uroplakin II in 80%
(71/89) of cases, with a positive correlation between GATA-
3 and uroplakin II H-score (0.44; p < 0.0001). All lesions
were positive for at least one marker, reinforcing the use of
these markers as a panel. In 35 patients with paired lymph
node metastasis, uroplakin II and GATA-3 were retained in
90% and 75% of patients, respectively, suggesting these
markers may have relatively high sensitivity in diagnosing
metastatic urothelial carcinoma. High intensity p40 immu-
nostain (3+), however, was significantly associated with
reduced patient survival (p = 0.03). These results suggest
that whereas GATA-3 and uroplakin II may be most useful
in the diagnosis of urothelial carcinoma metastasis, p40
may be additionally suited as a prognostic marker.
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Use of immunohistochemistry (IHC) in the context of
urothelial carcinoma (UCa) is primarily required in distin-
guishing UCa from secondary malignancies involving the
urinary tract and in correctly identifying the site of origin for
metastasis of unknown primary. Application of IHC markers
for assessment of metastatic risk and prognosis in UCa3025/Online ISSN 1465-3931 © 2016 Royal College of P
er the CC BY license (http://creativecommons.org/licenses
i.org/10.1016/j.pathol.2016.05.008remains limited. Recently, new antibodies targeting uropla-
kin II (UPII) and p40 have been developed and show high
sensitivity and speciﬁcity in the diagnosis of UCa;1–7 how-
ever, few analyses have assessed these markers in combina-
tion or in the setting of patient outcomes. In this study, we test
the ability of these markers, singly or in combination with
GATA-3, to improve diagnostic accuracy and outcomes
prediction in advanced UCa.
IHC markers commonly used in the diagnosis of muscle-
invasive UCa include uroplakin III (UPIII), GATA-3,
thrombomodulin, p63, high-molecular weight cytokeratins
and cytokeratin 7.8 UPIII shows the highest speciﬁcity of this
group, but is immunoreactive in only approximately 40–50%
of these cases.9,10 Improved sensitivity can be achieved
through a combination of IHC markers, although usefulness
in the diagnosis of metastatic lesions and variant morphol-
ogies tends to be less robust.
In the current study, we assess the ability of UPII, p40 and
GATA-3, individually and in combination, to label primary
and metastatic UCa and to evaluate the association of these
markers and patient prognosis.
MATERIALS AND METHODS
Patient material
Patients with invasive UCa were identiﬁed through database search at the
University of California at San Diego with approval from the Institutional
Review Board (Table 1). All cases were re-reviewed by two of the authors
(DH and ML). Of the 89 cystectomy cases included for evaluation, patho-
logical stage included pT2 (19; 20%); pT3 (62; 70%) and pT4 (6; 7%).
Variant morphology was excluded, including cases with divergent differen-
tiation. Patients included 71 men and 18 women with a mean age of 64 years
(range 43–85 years) and a mean follow-up of 25.3 months (range 1–83
months; median 18 months). Estimated median overall survival and
recurrence-free survival was 21.5 months [95% conﬁdence interval (CI)
15.4–29.5] and 18.5 months (95% CI 13.0–26.9), respectively. In addition,
10 specimens of normal urothelium were included for study and obtained
from patients with no prior or subsequent history of UCa.
Immunohistochemistry and scoring
We performed IHC on formalin ﬁxed, parafﬁn embedded tissue microarrays
(TMA) from normal urothelium (non-cancer patients) and patients with
bladder UCa. The TMA were assembled using an automated operated device
(TMA Master; 3DHOSTECH Ltd, Hungary) and contained four distinctive
1 mm diameter cores punched from each case. Four mm sections were cut intoathologists of Australasia. Published by Elsevier B.V. This is an open
/by/4.0/).
Table 1 Clinicopathological features
Features All patients
Gender
Male 71/89 (80%)
Female 18/89 (20%)
Age at diagnosis, years (range) 64 (43–85)
<75 59/89 (66%)
75 30/89 (34%)
Pathological T-stage
1, 2 21/89 (24%)
3, 4 68/89 (76%)
Carcinoma in situ
No 42/89 (47%)
Yes 47/89 (53%)
Positive margins
No 62/89 (70%)
Yes 27/89 (30%)
Neoadjuvant or adjuvant chemotherapy
No 54/89 (63%)
Yes 32/89 (37%)
Overall survival, months, median (range) 21.5 (15.4–29.5)
Recurrence-free survival, months, median (range) 18.5 (13.0–26.9)
Follow-up available 87/89 (98%)
Length of follow-up, months, median (range) 18 (1–83)
Patient with recurrent disease 32/87 (36%)
Total number of deaths 55/87 (62%)
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evaluation. Additional 4 mm sections were cut and deparafﬁnised in xylene
substitute and rehydrated via graded ethanol, followed by blocking of
endogenous peroxidases with 3% hydrogen peroxide solution. Heat-induced
antigen retrieval was performed using a modiﬁed citrate buffer formulation in
a pressure cooker. A standard IHC technique was performed using prediluted
mouse monoclonal UPII (clone BC21), GATA3 (clone L50-823), and p40
(clone BC28); all three primary antibodies were purchased from Biocare
Medical, USA. All primary antibodies were incubated at room temperature
for 30 min. Detection was performed with a rabbit anti-mouse IgG antibody
for 10 min, followed by a horseradish peroxidase polymer conjugate for
10 min. Visualisation was achieved with 3,30-diaminobenzidine (DAB).
GATA-3 and p40 immunostains were scored for nuclear expression,
whereas UPII immunostain was scored for cytoplasmic and membranous
staining. Immunohistochemical stain was characterised by intensity (0,
negative; 1, weak; 2, moderate; 3, strong) with 5% reactivity used as a cut-off.
H-score was also used to semiquantify immunostaining using the following
formula: (0 × % cells 0) + (1 × % cells 1+) + (2 × % cells 2+) + (3 × % cells
3+); resultant scores ranged from 0 to 300.11 The immunostains were scored
by two of the authors (ML and DH) and discrepant scores were re-evaluated
together in order to reach consensus.
Statistical analysis
The relationship between immunostain intensity (categorical) or H-score
(continuous) categories to clinicopathological features was performed using
the Fisher’s exact test for categorical variables andWilcoxon rank sum test for
continuous variables. Correlation between individual immunohistochemical
stains was performed using the Spearman correlation coefﬁcient. Statistical
analysis of IHC intensity or H-score relationship to outcomes (disease-spe-
ciﬁc recurrence and overall survival) was performed using the Logrank test
for categorical factors and Wald test from proportional hazards model for
continuous factors.
RESULTS
Immunoreactivity of UPII, GATA-3 and p40 in normal
urothelium
Normal urothelium showed a weakly cytoplasmic to mem-
branous staining pattern of UPII, with reactivity in theintermediate cell layer and more strongly within the umbrella
cell layer. GATA-3 was present in the full thickness of the
urothelium, whereas p40 was most highly expressed in the
basal and intermediate cells of the urothelium (Fig. 1).GATA-3, UPII and p40 expression in bladder urothelial
carcinoma
We categorised IHC by intensity (0–3+), as well as by H-
score. Bladder UCa showed an overall immunopositivity
rate of GATA-3 99% (88/89), p40 87% (77/89) and UPII
80% (71/89) (Table 2). When immunoreactivity was pre-
sent, the staining pattern was frequently uniform throughout
the tumour, with occasional patchy expression in the case
of UPII. All cases showed at least one marker to be
immunoreactive (Fig. 2). Whereas GATA-3 showed higher
intensity stain (2–3+) in 93% of the specimens, UPII and
p40 were less robust at 74% and 79% staining level 2–3+,
respectively. No signiﬁcant association was identiﬁed be-
tween IHC intensity in the 89 patients and clinicopatho-
logical features including gender, age, pathological stage,
presence of urothelial carcinoma in situ, and positive
margin status. Comparison of the relationship between
immunostains showed a positive correlation only between
GATA-3 and UPII (0.44; p < 0.0001; Spearman correlation
coefﬁcient).
We further subdivided our patient population into those
with and without lymph node metastases at the time of
cystectomy, which resulted in 43/89 patients (48%) with
metastatic disease and 46/89 patients (52%) without
(Table 2). Pathological features that were more likely in pa-
tients with metastatic disease included higher stage (pT3 and
pT4 stage; p = 0.01, Fisher’s exact test) and administration of
neoadjuvant or adjuvant chemotherapy (p < 0.001, Fisher’s
exact test). We also analysed the correlation between H-
scores and the presence or absence of lymph node metastasis
using Wilcoxon rank sum test; patients with lymph node
metastasis showed higher UPII H-score (average 160 versus
90; p = 0.007), lower p40 H-score (150 versus 220;
p = 0.001) and no statistically signiﬁcant difference in
GATA-3 level (250 versus 240; p = 0.35) in carcinoma cells
within the bladder.
UPII is most likely to be retained in metastatic lymph
node deposits
We analysed a subset of 35 patients who had both bladder
UCa and matched lymph node metastases to determine if
GATA-3, UPII and/or p40 expression is retained in meta-
static deposits. Even though a total of 43 patients had
documented metastatic disease, only 35 metastatic foci had
adequate tumour volume on TMA analysis to accurately
score all three immunomarkers. Expression of GATA-3,
UPII and p40 (any intensity from 1+ to 3+) was present in
the primary bladder tumour in 35/35 (100%), 32/35 (91%)
and 28/35 (80%) cases, respectively. Comparison to the
matched metastatic deposit showed highest retention of
UPII expression in the metastatic deposit. When compared
to the primary tumour, UPII was retained at similar levels in
29/32 metastatic lesions (90%), whereas GATA-3 was
retained in 26/35 metastases (74%) and p40 in 21/28 me-
tastases (75%).
Fig. 1 Histology of normal urothelium stained by haematoxylin and eosin and immunohistochemistry: UPII, p40 and GATA-3.
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reduced overall survival
Univariable analysis was performed to compare clinico-
pathological features and IHC parameters to recurrence-free
survival and overall survival. As anticipated, patients with
advanced age (75 years), higher pT stage (pT3 and pT4
disease), and presence of lymph node metastasis were asso-
ciated with reduced recurrence-free survival (p = 0.003,
p = 0.03, and p = 0.001, respectively; Logrank test) and
overall survival (p = 0.004, p = 0.02, and p = 0.0007,
respectively; Logrank test) (Table 3). Multivariable analysis
showed the presence of lymph node metastasis and age 75
years or greater showed reduced recurrence-free survival (HR
2.76; 95% CI 1.57–4.83 and HR 2.02; 95% CI 1.18–3.46,
respectively) and reduced overall survival (HR 3.09; 95% CI
1.72–5.54 and 2.15; 95% CI 1.24–3.71), respectively
(Table 4). Finally, we evaluated GATA-3, UPII and p40 as
prognostic markers of recurrence-free and overall survival.
Only strong p40 expression (3+ intensity) in the primary
bladder UCa showed an independent association with
reduced overall survival (p = 0.03) irrespective of lymph
node status (Fig. 3).DISCUSSION
Immunohistochemical analysis of urothelial carcinoma is of
diagnostic value in several settings, such as the exclusion of
secondary involvement of the bladder by carcinoma arising at
another site or in the identiﬁcation of the site of origin of
metastatic lesions of unknown primary. Historically, many
antibodies used in this context show lack of speciﬁcity, but
maintain utility when used as a diagnostic panel. Such anti-
bodies include high-molecular weight cytokeratins,cytokeratin 7, cytokeratin 20, p63, thrombomodulin and
GATA-3.8 More speciﬁc antibodies have gained wider
acceptance, including S100P,12 which is expressed in
urothelial and pancreaticobiliary lesions, and uroplakin III
(UPIII), which appears speciﬁc to urothelial origin.13 How-
ever, the lower sensitivity of both S100P and UPIII in
advanced high-grade bladder cancer14–16 has prompted the
development of new IHC markers. In this study, we assessed
the diagnostic and prognostic application of the more recently
developed uroplakin II and p40 antibodies in the setting of
advanced and metastatic urothelial carcinoma and tested the
additional value of GATA-3 incorporation into this panel.
A commercial UPII antibody has recently been developed
by Biocare Medical and several studies have assessed its
sensitivity relative to UPIII, as well as its usefulness as a
diagnostic IHC marker together with GATA-3.1–5 The
uroplakin proteins are highly conserved, transmembrane
proteins that function as key components of the urothelial
plaque.17–19 The relatively restrictive expression of these
proteins to the urothelium has generated long-standing in-
terest in diagnostic applications for urothelial carcinoma.10,20
For example, the ﬁrst primary antibody against UPII was
developed in rabbits and targeted a conserved bovine UPII
epitope in 1995; this antibody showed strong immunoreac-
tivity against the umbrella cell layer of normal human
urothelium and speciﬁcity for urothelial carcinoma versus
carcinomas arising in other sites.10
The newly commercialised UPII antibody shows similar
speciﬁcity, but with improved sensitivity over UPIII. UPII
versus UPIII sensitivity in invasive urothelial carcinoma of
the bladder was shown in one study on 16 cases to have a
sensitivity of 63% versus 19% and in another study of 174
cases of varying grades and stages to have a sensitivity of
Table 2 Association of pathological features, p40, UPII and GATA-3 expression with metastatic disease
No mets (n = 46) Mets (n = 43) pa
Pathological T-stage, n (%)
1, 2 16 (35%) 5 (12%)
3, 4 30 (65%) 38 (88%) 0.01
Neo- or adjuvant chemotherapy, n (%)
No 39 (85%) 15 (38%)
Yes 7 (15%) 25 (62%) 0.0001
Carcinoma in situ, n (%)
No 18 (39%) 24 (56%)
Yes 28 (61%) 19 (44%) 0.14
Positive margins, n (%)
No 34 (74%) 28 (65%)
Yes 12 (26%) 15 (35%) 0.49
p40 H-score, median (range) 220 (0–300) 150 (0–280) 0.001
UPII H-score, median (range) 90 (0–300) 160 (0–300) 0.007
GATA-3 H-score, median (range) 240 (10–300) 250 (0–300) 0.35
Mets, metastases; UPII, uroplakin II.
a Fisher’s exact test for categorical factors, Wilcoxon rank sum test for measured factors.
Fig. 2 Histology of invasive UCa using haematoxylin and eosin and immunohistochemical markers showing positive patterns (3+ score), where GATA-3 and p40
showed nuclear staining, and UPII showed diffused membranous and cytoplasmic expression.
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ranged from papillary urothelial neoplasm of low malignant
potential (PUNLMP) to high-grade papillary urothelial car-
cinoma, UPII was reported to stain >90% of cases,1 although
a separate report from the upper tract appeared to have UPII
retained primarily in umbrella cell layers of lower grade le-
sions.4 UPII also showed improved sensitivity over UPIII in
nested, plasmacytoid, micropapillary and sarcomatoid UCa,
although the number of plasmacytoid cases was somewhat
limited in two studies.4,5 Conventional invasive UCa shows a
range of immunoreactive frequency, with 44–78% of cases
reported to be positive for UPII.1,4,5 However, in all com-
parisons, UPII outperformed UPIII in sensitivity.
In our study we focused primarily on the use of UPII in the
diagnostically challenging setting of advanced bladder cancer
and used paired lymph node metastases to assess changes in
expression within an individual patient. When using any levelof immunoreactivity, 80% of muscle-invasive UCa were
positive for UPII, although this dropped to 74% when only
moderate to intense immunoreactivity was considered. When
used as a panel together with GATA-3 and p40, no primary
bladder carcinoma or metastatic lesion was negative for all
three markers. This suggests that a combination of GATA-3,
UPII and p40 used together with more conventional, but less
speciﬁc, immunohistochemical markers may be useful to
identify urothelial origin in challenging cases and may be
immunoreactive in a higher percentage of invasive UCa than
previously reported.2 In contrast to both GATA-3 and p40,
however, lymph node metastases were less likely to lose UPII
expression, thus making addition of UPII to evaluation of
metastases of unknown origin of potential value.
In conjunction with our analysis of UPII, we also incor-
porated another recently developed mouse monoclonal anti-
body against p40 (DNp63) by Biocare Medical (BC28) that
Table 3 Univariable analysis to compare clinicopathological features and patient outcomes
Factor Recurrence-free survival Overall survival
All patients pa All patients pa
Gender
Male 18.5 21.6
Female 18.7 0.07 21.2 0.84
Age at diagnosis 0.04 0.04
<75 26.8 28.5
75 13.04 0.003 13.4 0.004
LN mets
No 30.1 42.6
Yes 12.2 0.001 13.4 0.0007
Pathological T-stage
1,2 75.4 75.4
3,4 15.4 0.03 18.3 0.02
CIS
No 18.8 21.6
Yes 14.6 0.44 20.6 0.32
Positive margins
No 21.5 22.2
Yes 13.8 0.18 15.6 0.17
p40
H-score 0.88 0.62
Any level 3 staining
No 30.2 26.8
Yes 15.4 0.13 18.5 0.20
UPII
H-score 0.65 0.65
Any UPII staining
No 30.2 40.5
Yes 17.2 0.62 20.6 0.38
>30% level 2/3 staining
No 17.2 21.6
Yes 18.8 0.50 21.2 0.77
GATA-3
H-score 0.94 0.76
CIS, carcinoma in situ; LN, lymph node; Mets, metastases; UPII, uroplakin II.
a Log rank test.
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commercial antibodies.6 p40 represents a shorter isoform of
the TP63 gene product that lacks the transactivation domain
located within the N-terminus region (DNp63).21 Studies on
lung cancer specimens have shown that p40 expression was
restricted to squamous cell carcinoma and was highly asso-
ciated with p53 alterations.6,22–25 More recently, BC28 has
shown immunoreactivity in >80% of cases of skin cancer,
head and neck squamous carcinoma and urothelial carci-
noma, but an absence of expression in other cancers including
prostatic adenocarcinoma and breast cancer.6 The extent of
squamous differentiation in this UCa population was not
described, although p63 expression and its p40 isoform likely
share similar expression patterns in these tumour populations.
Although the use of p40 as part of a diagnostic panel may be
of value in UCa, its solitary application in this context may be
limited. In addition, use of this panel may also be of value in
challenging diagnostic settings, such as the distinction of
metastatic urothelial carcinoma from lung squamous cell
carcinoma.2
We tested the ability of GATA-3, UPII and p40 to predict
recurrence-free and overall survival, which included pro-
gressive metastatic disease in 43 of 89 patients and death of
disease in 55 of 89 patients. Given the frequent expression of
both GATA-3 and UPII in this population, no signiﬁcant
difference in the expression patterns of these two markers
using a cut-off of any versus no expression or low-level(0–1+) versus high-level (2–3+) expression was seen. In
contrast, high intensity p40 expression in the primary bladder
UCa was associated with signiﬁcantly shortened recurrence-
free and overall survival. Although not signiﬁcant in uni-
variate analysis, 3+ intensity of p40 staining was signiﬁcant
in multivariate analysis, which may be the result of unbal-
anced sample size, group variation or the presence of
interaction.26,27
Prior studies evaluating the prognostic role of p63 and p40
have yielded mixed results. Several studies have evaluated
the prognostic role of p63 in bladder cancer patients, with
p63 retention associated with either no effect or a worse
prognosis.28–30 Expression of the p40 (DNp63) protein has
been shown in two studies to confer a higher likelihood of
disease progression in muscle-invasive bladder cancer,28,30
although one recent study using patients with pT1 disease
showed that p40 expression loss is associated with a higher
risk of progression.29 The data from our study suggest that
p40 retention, at least in the context of advanced bladder
cancer, was associated with increased likelihood of pro-
gression and death from disease, irrespective of lymph node
status.
The oncogenic mechanism of p40 (DNp63) is not well
deﬁned, although a current study demonstrated a plausible
explanation31 and proposed that p40 is able to increase
mRNA and protein levels of MTSS1 (Metastasis suppressor
1; Missing in Metastasis; MIM/BEG4), a protein involved in
Table 4 Multivariable analysis to compare clinicopathological features and
p40 IHC properties with recurrence-free and overall survival
Hazard ratio (95% CI) pa
Recurrence-free survival
LN mets (No vs Yes) 2.76 (1.57–4.83) 0.0004
Age (<75 vs >75) 2.02 (1.18–3.46) 0.01
Any level 3 p40 staining (No vs Yes) 1.93 (1.07–3.46) 0.03
Overall survival
LN mets (No vs Yes) 3.09 (1.72–5.54) 0.0002
Age (<75 vs 75) 2.15 (1.24–3.71) 0.006
Any level 3 p40 staining (No vs Yes) 1.94 (1.08–3.51) 0.03
CI, conﬁdence interval; LN, lymph node; Mets, metastases.
a Wald test.
Fig. 3 Reduced overall survival of patients with strong p40 expression (3+
intensity), irrespective of lymph node metastasis. (A) Patient with lymph node
metastasis; (B) patient without lymph node metastasis.
548 LEIVO et al. Pathology (2016), 48(6), Octoberpromoting cell migration and invasion through reorganisa-
tion of the actin cytoskeleton. While in vitro pro-migratory
ability was demonstrated only in breast cancer cell lines,
the analysis of 138 bladder cancer samples also showed
strong correlation between DNp63 isoform and MTSS1
expression, suggesting that p40/MTSS1 axis could also beinvolved in cell migration and invasion of bladder cancer.
Another study suggests that retained and/or elevated p40
may be associated with a subset of aggressive urothelial
carcinomas that maintain expression of the miR200 family
and E-cadherin.28,32 Finally, p40 expression in UCa may be
related to underlying molecular subtypes of bladder cancer,
although this was not explored in our study. Speciﬁcally, the
expression of basal cell markers such as p63, and likely p40,
has been associated with an increased likelihood of aggres-
sive disease.33 Future studies that evaluate the persistent
expression of epithelial markers in advanced bladder cancer,
and their relationship to the epithelial-mesenchymal transi-
tion process and therapeutic response, are required to
address this question.
In conclusion, our study has shown that the newly devel-
oped UPII and p40 antibodies may be useful ancillary tools in
muscle-invasive and metastatic urothelial carcinoma. Addi-
tional studies that evaluate a larger prospective patient pop-
ulation with muscle-invasive bladder cancer may be of value,
especially in the context of the role of p40 in disease
progression.
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